1020658-79-0

Upstream product

• 1020658-78-9 4-(2-bromo-5-fluorophenoxy)piperidine-1-carbonitrile 

Downstream Products

• 1020658-80-3 methyl 5-{3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2,4-oxadiazol-5-yl}nicotinate 
• 1030613-43-4 4-(2-bromo-5-fluorophenoxy)-1-[5-(1H-pyrrol-3-yl)-[1,2,4]-oxadiazol-3-yl]piperidine 
• 1030613-70-7 methyl 3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-[1,2,4]-oxadiazole-5-carboxylate 
• 1030855-53-8 methyl (6E)-7-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-3,4,9-trioxo-2,5-dioxa-6,8-diazadec-6-en-10-oate 
• 1030613-74-1 4-(2-bromo-5-fluorophenoxy)-1-[5-(1H-pyrazol-3-yl)-[1,2,4]-oxadiazol-3-yl]piperidine 

Relevant academic research and scientific papers

AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Azacycloalkane derivatives of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase

Azacycloalkane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.